ES2033981T3 - Procedimiento para la preparacion de proteinas bifuncionales. - Google Patents

Procedimiento para la preparacion de proteinas bifuncionales.

Info

Publication number
ES2033981T3
ES2033981T3 ES198888105693T ES88105693T ES2033981T3 ES 2033981 T3 ES2033981 T3 ES 2033981T3 ES 198888105693 T ES198888105693 T ES 198888105693T ES 88105693 T ES88105693 T ES 88105693T ES 2033981 T3 ES2033981 T3 ES 2033981T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
bifunctional proteins
proteins
bifunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888105693T
Other languages
English (en)
Spanish (es)
Inventor
Paul Dr. Habermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2033981T3 publication Critical patent/ES2033981T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES198888105693T 1987-04-16 1988-04-09 Procedimiento para la preparacion de proteinas bifuncionales. Expired - Lifetime ES2033981T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873712985 DE3712985A1 (de) 1987-04-16 1987-04-16 Bifunktionelle proteine

Publications (1)

Publication Number Publication Date
ES2033981T3 true ES2033981T3 (es) 1993-04-01

Family

ID=6325799

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888105693T Expired - Lifetime ES2033981T3 (es) 1987-04-16 1988-04-09 Procedimiento para la preparacion de proteinas bifuncionales.

Country Status (20)

Country Link
EP (1) EP0288809B1 (enExample)
JP (1) JP2667193B2 (enExample)
KR (1) KR970000187B1 (enExample)
AR (1) AR242991A1 (enExample)
AT (1) ATE79135T1 (enExample)
AU (1) AU613022B2 (enExample)
CA (1) CA1322157C (enExample)
DE (2) DE3712985A1 (enExample)
DK (1) DK170741B1 (enExample)
ES (1) ES2033981T3 (enExample)
FI (1) FI98830C (enExample)
GR (1) GR3006141T3 (enExample)
HU (1) HU204303B (enExample)
IE (1) IE61574B1 (enExample)
IL (1) IL86086A (enExample)
NO (1) NO176922C (enExample)
NZ (1) NZ224247A (enExample)
PH (1) PH25327A (enExample)
PT (1) PT87237B (enExample)
ZA (1) ZA882659B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) * 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU1551801A (en) * 1999-11-30 2001-06-12 Shionogi & Co., Ltd. Chemokine slc-il2 fused protein and gene thereof
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
EP1366067B1 (en) 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DK2279755T3 (da) 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
BRPI0317376B8 (pt) 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
EP1944318B1 (en) * 2003-07-21 2011-03-02 Transgene S.A. Multifunctional cytokines
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
WO2010001414A1 (en) * 2008-07-03 2010-01-07 Lupin Limited Expression of heterologous proteins in bacterial system using a gm-csf fusion tag

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8327880D0 (en) * 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
WO1985004673A1 (fr) * 1984-04-10 1985-10-24 Takeda Chemical Industries, Ltd. Nouvel adn et son utilisation
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JPS61128889A (ja) * 1984-11-27 1986-06-16 Green Cross Corp:The 組換えdna及び該dnaによる形質転換体
JPH0646957B2 (ja) * 1985-03-11 1994-06-22 武田薬品工業株式会社 インタ−ロイキン−2の製造方法
WO1987002060A1 (en) * 1985-10-03 1987-04-09 Biogen N.V. Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
GR3006141T3 (enExample) 1993-06-21
DK170741B1 (da) 1996-01-08
JP2667193B2 (ja) 1997-10-27
KR970000187B1 (ko) 1997-01-06
FI98830C (fi) 1997-08-25
IL86086A0 (en) 1988-09-30
DK209188D0 (da) 1988-04-15
NO176922B (no) 1995-03-13
HUT47319A (en) 1989-02-28
IE61574B1 (en) 1994-11-16
NO881658D0 (no) 1988-04-15
NO881658L (no) 1988-10-17
KR880012760A (ko) 1988-11-29
ZA882659B (en) 1988-10-14
NO176922C (no) 1995-06-21
FI98830B (fi) 1997-05-15
PT87237B (pt) 1992-07-31
EP0288809B1 (de) 1992-08-05
FI881743L (fi) 1988-10-17
IE881146L (en) 1988-10-16
ATE79135T1 (de) 1992-08-15
PT87237A (pt) 1988-05-01
IL86086A (en) 1995-01-24
PH25327A (en) 1991-04-30
AU613022B2 (en) 1991-07-25
AR242991A1 (es) 1993-06-30
JPS63301898A (ja) 1988-12-08
CA1322157C (en) 1993-09-14
NZ224247A (en) 1990-04-26
HU204303B (en) 1991-12-30
FI881743A0 (fi) 1988-04-14
DK209188A (da) 1988-10-17
DE3873397D1 (de) 1992-09-10
EP0288809A1 (de) 1988-11-02
DE3712985A1 (de) 1988-11-03
AU1466188A (en) 1988-10-20

Similar Documents

Publication Publication Date Title
ES2033981T3 (es) Procedimiento para la preparacion de proteinas bifuncionales.
BG46601A3 (bg) Метод за получаване на авермектинови производни
FI870219A0 (fi) Hypoglykemiska tiazolidindioner.
NO175620C (no) Fremgangsmåte for fremstilling av et antitumorvirksomt legemiddel
NL193981B (nl) 7-(eventueel gesubstitueerd naftyl)-3-methyl-octa-2,4,6-trieenderivaten met retineachtige werking alsmede farmaceutische en kosmetische preparaten die dergelijke derivaten bevatten.
EP0675136A3 (en) Antibodies to mammalian interleukin-4 and peptides useful as antigens in their production.
FI99015B (fi) Menetelmä biologisesti aktiivisen kasvaimen nekroositekijä-proteiinin muteiinin valmistamiseksi
DE3674906D1 (de) Selbstklemmende medizinische prothese und ihre herstellung.
FI830100A0 (fi) Nya 6-substituerade s-triazolo /3,4-a/ ftalazinderivat
NO831317L (no) Fremgangsmaate for fremstilling av funksjonelle menneske-urokinase proteiner.
ATE82857T1 (de) Interleukin-2-zusammensetzungen.
BG46599A3 (en) Method for preparing of benzene azetonitriles
DE3668168D1 (de) Desmosinderivate und reagenz zur herstellung artifizieller antigene.
IT1196988B (it) Policarbonati ramificati contenenti composti metilen-bis-naftalenici e procedimento per la loro preparazione
EP0336779A3 (en) Polypeptides stabilized by covalent hydrogen bond replacements
BG44379A3 (en) Method for preparing of 9- chlor- 1, 5- benzothiazepine derivatives
FR2581543B1 (fr) Pharmacotechnie permettant la realisation d'une preparation insulinique active par voie orale
FR2582544B1 (fr) Procede de preparation de supports spheriques de catalyseurs et matieres ainsi produites
DE3674789D1 (de) Balken und dessen herstellung.
ES2065898T3 (es) Metodo para preparar dodecahidro-3a,6,6,9a-tetrametilnafto(2,1-b)furano y nuevos haloetil decalin derivados.
IT8522730A0 (it) Ferro-derivati della globina e dell'acetilglobina dotati di elevata biodisponibilita', processo di preparazione e composizioni farmaceutiche.
DE58909720D1 (de) Neoglykoproteine, ihre Herstellung und Verwendung
DE3671630D1 (de) Glycero-3(2)-phospho-l-serinderivate und diese enthaltende pharmazeutischen praeparate.
BG44029A3 (en) Method for preparing of n- dimethyl morphinanic derivatives
ATE137487T1 (de) Komplexe, enthaltend s(+)-phenyl-alkansäuren und alpha-hydroxy-alkansäuren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 288809

Country of ref document: ES